Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Inactivation of Smad4 is a prognostic factor in intrahepatic cholangiocarcinoma.

Yan XQ, Zhang W, Zhang BX, Liang HF, Zhang WG, Chen XP.

Chin Med J (Engl). 2013 Aug;126(16):3039-43.

PMID:
23981608
2.
3.
4.

A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables.

Okabayashi T, Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Takayama T, Makuuchi M.

Cancer. 2001 Nov 1;92(9):2374-83.

PMID:
11745293
6.

Smad4 may help to identify a subset of colorectal cancer patients with early recurrence after curative therapy.

Ahn BK, Jang SH, Paik SS, Lee KH.

Hepatogastroenterology. 2011 Nov-Dec;58(112):1933-6. doi: 10.5754/hge11186.

PMID:
22024061
7.

Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma.

Wakai T, Shirai Y, Sakata J, Matsuda Y, Korita PV, Takamura M, Ajioka Y, Hatakeyama K.

Int J Clin Exp Pathol. 2011 Apr;4(4):363-70. Epub 2011 Apr 10.

8.

[The role of Smad4 and MAPK proteins in signal transduction pathway in non-small cell lung cancer].

Tong XD, Liu HX, Zhao HR, Xu SG, Li Y, Han LB, Zhang L.

Zhonghua Zhong Liu Za Zhi. 2006 Oct;28(10):741-5. Chinese.

PMID:
17366784
9.

Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus.

Natsugoe S, Xiangming C, Matsumoto M, Okumura H, Nakashima S, Sakita H, Ishigami S, Baba M, Takao S, Aikou T.

Clin Cancer Res. 2002 Jun;8(6):1838-42.

10.

Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma.

Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E, Llamas-Gutierrez F, Meunier B, Boudjema K, Clément B, Coulouarn C.

Hepatology. 2013 Dec;58(6):1992-2000. doi: 10.1002/hep.26577. Epub 2013 Oct 17.

PMID:
23775819
11.

Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.

Shimonishi T, Isse K, Shibata F, Aburatani I, Tsuneyama K, Sabit H, Harada K, Miyazaki K, Nakanuma Y.

Hepatology. 2000 Oct;32(4 Pt 1):761-9.

PMID:
11003620
12.

Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): importance of preoperatively- determined anatomic invasion level and number of tumors.

Marubashi S, Gotoh K, Takahashi H, Ohigashi H, Yano M, Ishikawa O, Sakon M.

Dig Dis Sci. 2014 Jan;59(1):201-13.

PMID:
24122559
13.

Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma.

Maeda T, Taguchi K, Aishima S, Shimada M, Hintz D, Larusso N, Gores G, Tsuneyoshi M, Sugimachi K, Wands JR, de la Monte SM.

Cancer Detect Prev. 2004;28(5):313-8.

PMID:
15542253
14.

Fatty acid-binding protein 5 promotes cell proliferation and invasion in human intrahepatic cholangiocarcinoma.

Jeong CY, Hah YS, Cho BI, Lee SM, Joo YT, Jung EJ, Jeong SH, Lee YJ, Choi SK, Ha WS, Park ST, Hong SC.

Oncol Rep. 2012 Oct;28(4):1283-92. doi: 10.3892/or.2012.1922. Epub 2012 Jul 19.

PMID:
22825302
15.

Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma.

Chen YL, Jeng YM, Hsu HC, Lai HS, Lee PH, Lai PL, Yuan RH.

Int J Surg. 2013;11(1):85-91. doi: 10.1016/j.ijsu.2012.11.021. Epub 2012 Dec 13.

16.

Expression of DPC4/Smad4 gene in stone-containing intrahepatic bile duct.

Lee KT, Chang WT, Wang SN, Chuang SC, Chai CY, Hu SW.

J Surg Oncol. 2006 Sep 15;94(4):338-43.

PMID:
16917866
17.

Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling.

Torbenson M, Marinopoulos S, Dang DT, Choti M, Ashfaq R, Maitra A, Boitnott J, Wilentz RE.

Hum Pathol. 2002 Sep;33(9):871-6.

PMID:
12378510
18.

Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.

Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, Chen XH, Zhou Y, Fan J.

Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27.

PMID:
22451237
19.

[Smad4 and TGF-beta1 expression and clinical significance in bladder transitional cell carcinoma].

Tang ZY, Yang LY, Zhang YJ, Peng KL, Qi L.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006 Jun;31(3):363-6. Chinese.

20.

The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma.

Park BK, Paik YH, Park JY, Park KH, Bang S, Park SW, Chung JB, Park YN, Song SY.

Am J Clin Oncol. 2006 Apr;29(2):138-42.

PMID:
16601431

Supplemental Content

Support Center